ASX - By Stock
|
PIQ |
Re:
Ann: Update on study presented at ADA Conference
|
|
no vice
|
32 |
10K |
4 |
03/07/21 |
03/07/21 |
ASX - By Stock
|
32
|
10K
|
4
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Update on study presented at ADA Conference
|
|
no vice
|
32 |
10K |
6 |
03/07/21 |
03/07/21 |
ASX - By Stock
|
32
|
10K
|
6
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Update on study presented at ADA Conference
|
|
no vice
|
32 |
10K |
2 |
02/07/21 |
02/07/21 |
ASX - By Stock
|
32
|
10K
|
2
|
|
ASX - By Stock
|
PIQ |
Re:
Use the hype - be ready to sell
|
|
no vice
|
40 |
9.7K |
2 |
26/06/21 |
26/06/21 |
ASX - By Stock
|
40
|
9.7K
|
2
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics bolsters executive team - CCO and CFO appointed
|
|
no vice
|
89 |
22K |
0 |
24/06/21 |
24/06/21 |
ASX - By Stock
|
89
|
22K
|
0
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics bolsters executive team - CCO and CFO appointed
|
|
no vice
|
89 |
22K |
1 |
23/06/21 |
23/06/21 |
ASX - By Stock
|
89
|
22K
|
1
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics bolsters executive team - CCO and CFO appointed
|
|
no vice
|
89 |
22K |
1 |
18/06/21 |
18/06/21 |
ASX - By Stock
|
89
|
22K
|
1
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics bolsters executive team - CCO and CFO appointed
|
|
no vice
|
89 |
22K |
4 |
18/06/21 |
18/06/21 |
ASX - By Stock
|
89
|
22K
|
4
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics bolsters executive team - CCO and CFO appointed
|
|
no vice
|
89 |
22K |
2 |
16/06/21 |
16/06/21 |
ASX - By Stock
|
89
|
22K
|
2
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics bolsters executive team - CCO and CFO appointed
|
|
no vice
|
89 |
22K |
2 |
16/06/21 |
16/06/21 |
ASX - By Stock
|
89
|
22K
|
2
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics bolsters executive team - CCO and CFO appointed
|
|
no vice
|
89 |
22K |
1 |
15/06/21 |
15/06/21 |
ASX - By Stock
|
89
|
22K
|
1
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics bolsters executive team - CCO and CFO appointed
|
|
no vice
|
89 |
22K |
0 |
15/06/21 |
15/06/21 |
ASX - By Stock
|
89
|
22K
|
0
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics bolsters executive team - CCO and CFO appointed
|
|
no vice
|
89 |
22K |
1 |
15/06/21 |
15/06/21 |
ASX - By Stock
|
89
|
22K
|
1
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics bolsters executive team - CCO and CFO appointed
|
|
no vice
|
89 |
22K |
3 |
12/06/21 |
12/06/21 |
ASX - By Stock
|
89
|
22K
|
3
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics bolsters executive team - CCO and CFO appointed
|
|
no vice
|
89 |
22K |
4 |
11/06/21 |
11/06/21 |
ASX - By Stock
|
89
|
22K
|
4
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics bolsters executive team - CCO and CFO appointed
|
|
no vice
|
89 |
22K |
4 |
11/06/21 |
11/06/21 |
ASX - By Stock
|
89
|
22K
|
4
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics International seeks FDA approval for PromarkerD
|
|
no vice
|
322 |
97K |
0 |
09/06/21 |
09/06/21 |
ASX - By Stock
|
322
|
97K
|
0
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics International seeks FDA approval for PromarkerD
|
|
no vice
|
322 |
97K |
0 |
09/06/21 |
09/06/21 |
ASX - By Stock
|
322
|
97K
|
0
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics International seeks FDA approval for PromarkerD
|
|
no vice
|
322 |
97K |
3 |
08/06/21 |
08/06/21 |
ASX - By Stock
|
322
|
97K
|
3
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics International seeks FDA approval for PromarkerD
|
|
no vice
|
322 |
97K |
4 |
08/06/21 |
08/06/21 |
ASX - By Stock
|
322
|
97K
|
4
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics secures major analytical services contract
|
|
no vice
|
7 |
4.0K |
5 |
18/05/21 |
18/05/21 |
ASX - By Stock
|
7
|
4.0K
|
5
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics files US FDA 513(g) regulatory submission
|
|
no vice
|
37 |
12K |
1 |
11/05/21 |
11/05/21 |
ASX - By Stock
|
37
|
12K
|
1
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics files US FDA 513(g) regulatory submission
|
|
no vice
|
37 |
12K |
4 |
11/05/21 |
11/05/21 |
ASX - By Stock
|
37
|
12K
|
4
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics files US FDA 513(g) regulatory submission
|
|
no vice
|
37 |
12K |
2 |
09/05/21 |
09/05/21 |
ASX - By Stock
|
37
|
12K
|
2
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics files US FDA 513(g) regulatory submission
|
|
no vice
|
37 |
12K |
3 |
09/05/21 |
09/05/21 |
ASX - By Stock
|
37
|
12K
|
3
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics files US FDA 513(g) regulatory submission
|
|
no vice
|
37 |
12K |
1 |
04/05/21 |
04/05/21 |
ASX - By Stock
|
37
|
12K
|
1
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics files US FDA 513(g) regulatory submission
|
|
no vice
|
37 |
12K |
2 |
04/05/21 |
04/05/21 |
ASX - By Stock
|
37
|
12K
|
2
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics files US FDA 513(g) regulatory submission
|
|
no vice
|
37 |
12K |
1 |
04/05/21 |
04/05/21 |
ASX - By Stock
|
37
|
12K
|
1
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics files US FDA 513(g) regulatory submission
|
|
no vice
|
37 |
12K |
8 |
04/05/21 |
04/05/21 |
ASX - By Stock
|
37
|
12K
|
8
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics files US FDA 513(g) regulatory submission
|
|
no vice
|
37 |
12K |
1 |
29/04/21 |
29/04/21 |
ASX - By Stock
|
37
|
12K
|
1
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: ISO 13485 certification received - Manufacturing Update
|
|
no vice
|
19 |
5.8K |
0 |
23/04/21 |
23/04/21 |
ASX - By Stock
|
19
|
5.8K
|
0
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: ISO 13485 certification received - Manufacturing Update
|
|
no vice
|
19 |
5.8K |
6 |
23/04/21 |
23/04/21 |
ASX - By Stock
|
19
|
5.8K
|
6
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Exercise of Options
|
|
no vice
|
57 |
20K |
3 |
20/04/21 |
20/04/21 |
ASX - By Stock
|
57
|
20K
|
3
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Exercise of Options
|
|
no vice
|
57 |
20K |
7 |
19/04/21 |
19/04/21 |
ASX - By Stock
|
57
|
20K
|
7
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Exercise of Options
|
|
no vice
|
57 |
20K |
7 |
17/04/21 |
17/04/21 |
ASX - By Stock
|
57
|
20K
|
7
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Exercise of Options
|
|
no vice
|
57 |
20K |
1 |
13/04/21 |
13/04/21 |
ASX - By Stock
|
57
|
20K
|
1
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Exercise of Options
|
|
no vice
|
57 |
20K |
1 |
13/04/21 |
13/04/21 |
ASX - By Stock
|
57
|
20K
|
1
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Exercise of Options
|
|
no vice
|
57 |
20K |
1 |
05/04/21 |
05/04/21 |
ASX - By Stock
|
57
|
20K
|
1
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Exercise of Options
|
|
no vice
|
57 |
20K |
2 |
05/04/21 |
05/04/21 |
ASX - By Stock
|
57
|
20K
|
2
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Exercise of Options
|
|
no vice
|
57 |
20K |
7 |
03/04/21 |
03/04/21 |
ASX - By Stock
|
57
|
20K
|
7
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Exercise of Options
|
|
no vice
|
57 |
20K |
4 |
30/03/21 |
30/03/21 |
ASX - By Stock
|
57
|
20K
|
4
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Exercise of Options
|
|
no vice
|
57 |
20K |
6 |
30/03/21 |
30/03/21 |
ASX - By Stock
|
57
|
20K
|
6
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Exercise of Options
|
|
no vice
|
57 |
20K |
2 |
26/03/21 |
26/03/21 |
ASX - By Stock
|
57
|
20K
|
2
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Exercise of Options
|
|
no vice
|
57 |
20K |
0 |
26/03/21 |
26/03/21 |
ASX - By Stock
|
57
|
20K
|
0
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Exercise of Options
|
|
no vice
|
57 |
20K |
6 |
17/03/21 |
17/03/21 |
ASX - By Stock
|
57
|
20K
|
6
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Investor Presentation
|
|
no vice
|
34 |
10K |
6 |
13/03/21 |
13/03/21 |
ASX - By Stock
|
34
|
10K
|
6
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Investor Presentation
|
|
no vice
|
34 |
10K |
2 |
12/03/21 |
12/03/21 |
ASX - By Stock
|
34
|
10K
|
2
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Investor Presentation
|
|
no vice
|
34 |
10K |
3 |
10/03/21 |
10/03/21 |
ASX - By Stock
|
34
|
10K
|
3
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Investor Presentation
|
|
no vice
|
34 |
10K |
3 |
09/03/21 |
09/03/21 |
ASX - By Stock
|
34
|
10K
|
3
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics International seeks FDA approval for PromarkerD
|
|
no vice
|
322 |
97K |
2 |
08/03/21 |
08/03/21 |
ASX - By Stock
|
322
|
97K
|
2
|
|